`Case 1:24-cv-00733-MN Document 28-5
`Filed 11/25/24
`Page 1 of 3 PagelD #: 1644
`
`EXHIBIT N
`EXHIBIT N
`
`
`
`Case 1:24-cv-00733-MN Document 28-5 Filed 11/25/24 Page 2 of 3 PageID #: 1645
`Case 1:24-cv-00733-MN Document 28-5
`Filed 11/25/24
`Page 2 of 3 PagelD #: 1645
`
`REMARKS
`
`This communication is in response to the Non-Final Office Action dated August 16,
`
`2023. In the Office Action:
`
`-
`
`-
`
`-
`
`claims 2 and 16 were rejected under 112(b),
`
`claims 1-20 were rejected under obviousness-type double patenting, and
`
`claims 1, 3-16, and 17-20 were foundto be allowable.
`
`In this response, claims 2 and 16 have been amended. Support for the amendments can be
`
`found in the original disclosure; no new matter has been added. Upon entry ofthis response,
`
`claims 1-20 are pending.
`
`Claims 2 and 16 have been amendedtoclarify the acronyms.
`
`112(b) Rejection
`
`
`
`Allowable Subject Matter
`
`The Applicant acknowledgesthe allowability of claims 1, 3-15, and 17-20.
`
`Uponentry of this response, claims 1-20 are pending.
`
`McKessonStatement
`
`In view ofMcKesson Information Solutions v. Bridge Medical (Fed. Cir. 2007), the
`
`Applicant wishes to inform the Examinerthat the prosecution history of the following US Patent
`
`Applications may contain information relevant to the pending application:
`
`14/214644*, 14/320534, 14/335762, 14/611065, 14/641236, 14/321717, 14/321724,
`
`14/321733, 14/456683, 14/968703*, 14/614336, 14/458192, 14/458199*, 15/893514,
`
`15/435228, 15/878352*, 15/603400*, 15/406492*, 16/029483, 15/956741, 16/681673,
`
`16/748727, 16/750477, 16/934933*, 17/529111, 17/147305, 16/934392, 17/216399,
`
`17/973506, 17/968672, 17/973505, 17/443802, 17983311, 17/985832, 17/654732*,
`
`17/978894, 17/963170, 17/973507, 18/197070, 18/197071
`
`The Examineris encouraged to review the art madeof record, office actions, and notices
`
`of allowance, if any, in the above-mentioned applications.
`
`104402-5075-US
`
`-7-
`
`Response to Office Action
`
`
`
`Case 1:24-cv-00733-MN Document 28-5 Filed 11/25/24 Page 3 of 3 PageID #: 1646
`Case 1:24-cv-00733-MN Document 28-5
`Filed 11/25/24
`Page 3 of 3 PagelD #: 1646
`
`In addition, applications marked with an asterisk (*) have been or are currently being
`
`challenged at the PTAB. The Examineris encouraged to review the record of each of these
`
`proceedings in the Patent Trial and Appeal Case Tracking System (P-TACTS).
`
`Concluding Remarks
`
`By responding in the foregoing remarks only to particular positions asserted by the
`
`examiner, the Applicant does not necessarily acquiesce in other positions that have not been
`
`explicitly addressed. In addition, the Applicant’s arguments for the patentability of a claim
`
`should not be understood as implying that no other reasons for the patentability of that claim
`
`exist.
`
`In light of the above amendments and remarks, the Applicant respectfully requests that
`
`the Examinerreconsiderthis application with a view towards allowance. The Examineris
`
`invited to call the undersigned attorney at (650) 843-4000, if a telephonecall could help resolve
`
`any remaining items.
`
`Respectfully submitted,
`
`
`Date:|November 15, 2023 /Douglas J. Crisman/ 39,951
`
`Douglas J. Crisman
`(Reg. No.)
`MORGAN,LEWIS & BOCKIUS LLP
`1400 Page Mill Road
`Palo Alto, CA 94304
`Phone: (650) 843-4000
`
`104402-5075-US
`
`-8-
`
`Response to Office Action
`
`